Welcome to Paid Research Studies




  • Condition:   Hematopoietic Stem Cell Transplantation
    Intervention:   Drug: Melphalan
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting

  • Condition:   Amyloidosis; Systemic
    Intervention:   Drug: Propylene Glycol-Free Melphalan Hydrochloride
    Sponsors:   Shayna Sarosiek;   Spectrum Pharmaceuticals, Inc
    Recruiting

  • Conditions:   Cancer, Appendiceal;   ColoRectal Cancer
    Interventions:   Drug: Mitomycin c;   Drug: Melphalan
    Sponsor:   University of Kansas Medical Center
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Other: Pharmacological Study
    Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Multiple Myeloma;   Amyloidosis
    Interventions:   Device: Melphalan;   Drug: Pegfilgrastim;   Procedure: Autologous Hematopoietic Progenitor Cell Transplant
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Spectrum Pharmaceuticals, Inc
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Melphalan;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Keratinocyte Growth Factor (KGF)
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Evomela;   Procedure: Autologous Stem Cell Infusion;   Drug: G-CSF;   Drug: Palifermin
    Sponsors:   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
    Not yet recruiting

  • Condition:   Lymphoma
    Interventions:   Drug: rituximab;   Drug: bendamustine;   Drug: melphalan;   Procedure: Autologous Stem Cell Transplantation (ASCT)
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melphalan;   Drug: Bortezomib
    Sponsor:   Hackensack Meridian Health
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Busulfan IV;   Drug: Melphalan IV
    Sponsors:   Loyola University;   Amgen
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Other: Ascorbate;   Drug: Melphalan
    Sponsors:   Yogesh Jethava;   University of Iowa
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Drug: melphalan
    Sponsors:   Weill Medical College of Cornell University;   Celgene
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Selinexor;   Drug: Melphalan;   Drug: Dexamethasone;   Procedure: Autologous Hematopoietic Cell Transplantation (HCT);   Drug: Fosaprepitant
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Karyopharm Therapeutics Inc
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Allopurinol;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan
    Sponsor:   Swedish Medical Center
    Recruiting

  • Conditions:   Multiple Myeloma;   Auto Stem Cell Transplant
    Intervention:   Drug: Bortezomib
    Sponsor:   Hackensack Meridian Health
    Recruiting

  • Conditions:   Hematological Malignancy Undergoing a Related Donor Haploidentical HCT;   Leukemia;   Multiple Myeloma;   Lymphoma
    Interventions:   Drug: Evomela;   Drug: Fludarabine;   Radiation: Total Body Irradiation
    Sponsor:   Medical College of Wisconsin
    Recruiting

  • Conditions:   Hematologic Malignancies;   Nonmalignant Diseases;   Immunodeficiencies;   Hemoglobinopathies;   Genetic Inborn Errors of Metabolism;   Fanconi's Anemia;   Thalassemia;   Sickle Cell Disease
    Intervention:  
    Sponsor:   University of California, San Francisco
    Recruiting

  • Conditions:   Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Oligoastrocytoma;   Recurrent Adult Brain Neoplasm
    Interventions:   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mannitol;   Drug: Melphalan;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bile Duct Cancer;   Intrahepatic Cholangiocarcinoma
    Interventions:   Combination Product: Melphalan/HDS;   Drug: Cisplatin and Gemcitabine
    Sponsor:   Delcath Systems Inc.
    Recruiting

  • Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hematologic Malignancy
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Total Marrow Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Plasma Cell Leukemia;   Plasmacytoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Panobinostat;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   HLA-DP4 Positive Cells Present;   Platinum-Resistant Ovarian Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Aldesleukin;   Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes;   Other: Cellular Therapy;   Drug: Melphalan
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-Malignant Hematologic Disorders
    Interventions:   Drug: Melphalan;   Drug: Thiotepa;   Drug: Clofarabine;   Drug: Fludarabine;   Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®);   Procedure: CliniMACS reagents
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Immune Deficiency Disorders;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorders;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
    Intervention:   Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Multiple Myeloma
    Intervention:   Drug: BeEAM
    Sponsors:   Northside Hospital, Inc.;   Teva Pharmaceuticals USA
    Recruiting

  • Conditions:   Nausea;   Vomiting
    Interventions:   Drug: Aprepitant;   Drug: Olanzapine;   Drug: Aprepitant plus Olanzapine
    Sponsor:   Rush University Medical Center
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Transformed Indolent Non-Hodgkin Lymphoma
    Interventions:   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Venetoclax
    Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Leukemia, Myeloid, Acute;   Leukemia, Relapsed Adult Acute Myeloid;   Myelodysplastic Syndromes, Previously Treated
    Interventions:   Drug: CPX-351;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit Anti-Human T-Lymphocyte Globulin;   Biological: Haplo-Cord Stem Cell Transplantation
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Plasma Cell Myeloma;   Secondary Amyloidosis
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Melphalan;   Biological: Daratumumab;   Other: Laboratory Biomarker Analysis
    Sponsors:   City of Hope Medical Center;   Janssen, LP
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Drug: Pembrolizumab
    Sponsors:   Northside Hospital, Inc.;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Primary Immunodeficiency (PID);   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Inflammatory Conditions
    Interventions:   Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Hematopoietic Stem Cell Transplant (HSCT)
    Interventions:   Drug: Reduced-Intensity Conditioning Regimen;   Drug: Myeloablative Conditioning Regimen
    Sponsor:   Randy Windreich
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Biological: Autologous stem cell infusion;   Biological: Granulocyte colony stimulating factor;   Radiation: Radiation therapy;   Drug: Isotretinoin (13-cis-retinoic acid);   Drug: Melphalan;   Drug: Etoposide
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Autoimmune Disease;   Neurologic Autoimmune Disease;   Autologous Transplant Autoimmune;   Multiple Sclerosis Transplant;   MS Stem Cell Transplant;   Multiple Sclerosis Stem Cell Transplant;   Stiff Person Syndrome;   HCT for Neurologic Autoimmune Disorders;   CIDP Transplant;   Myasthenia Gravis Transplant
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Prednisone;   Procedure: Syngeneic Bone Marrow Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Blinatumomab;   Procedure: Autologous stem cell transplant;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral blood draws
    Sponsors:   Washington University School of Medicine;   Amgen
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hematologic Malignancy
    Interventions:   Drug: melphalan;   Drug: fludarabine;   Drug: thiotepa;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Mycophenolate Mofetil;   Drug: Filgrastim;   Drug: Tacrolimus
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Radiation: total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Clofarabine;   Procedure: (CliniMACS) T-cell depleted PBSC Transplant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS);   NK-Cell Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma (NHL);   Juvenile Myelomonocytic Leukemia (JMML);   Chronic Myeloid Leukemia (CML)
    Interventions:   Drug: Cyclophosphamide;   Biological: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Biological: G-csf;   Drug: Mesna;   Device: CliniMACS;   Biological: ATG (rabbit);   Drug: Blinatumomab;   Biological: TCRα/β+;   Biological: CD19+;   Biological: CD45RA-depleted DLI
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Refractory and/or Relapsed Metastatic Solid Tumors
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: low dose total body irradiation;   Drug: Melphalan;   Drug: Tacrolimus
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Acute Lymphoid Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML);   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Radiation: Hyperfractionated total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Clofarabine;   Procedure: HPC(A) stem cell allograft;   Drug: Rituximab;   Device: Rabbit antithymocyte globulin
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Yttrium Y 90 Basiliximab;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Drug: Etoposide;   Drug: BCNU;   Drug: AraC;   Drug: Melphalan;   Procedure: Peripheral blood stem cell transplantation;   Biological: G-CSF;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Carmustine;   Drug: Etoposide;   Drug: Melphalan;   Drug: Cytarabine;   Drug: Alemtuzumab;   Biological: Autologous Stem Cell Transplantation;   Biological: Allogeneic Stem Cell Transplantation;   Drug: Rituximab
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Melphalan;   Drug: Etoposide;   Drug: Carboplatin;   Biological: Autologous Stem Cell Infusion;   Biological: Granulocyte colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Syndromes;   Chronic Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Large Granulocytic Leukemia
    Intervention:   Procedure: Allogeneic transplantation
    Sponsor:   Scripps Health
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Juvenile Myelomonocytic Leukemia (JMML);   Acute Lymphoblastic Leukemia (ALL);   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Gene Mutations;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS;   Drug: Sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Busulfan;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Olaparib;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacokinetic Study;   Biological: Rituximab;   Drug: Vorinostat
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: Mycophenolate mofetil
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Thalidomide;   Drug: Dexamethasone;   Drug: Daratumumab;   Drug: Cisplatin;   Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Melphalan;   Procedure: ASCT;   Drug: Lenalidomide;   Drug: Bortezomib
    Sponsors:   University of Arkansas;   Janssen, LP
    Recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aplastic Anemia;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Secondary Myelofibrosis;   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Blasts 15 Percent or Less of Bone Marrow Nucleated Cells;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin;   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting

  • Conditions:   Non Malignant Diseases;   Immunodeficiencies;   Hemoglobinopathies
    Interventions:   Drug: RIC: Distal Campath;   Drug: RIC:Intermediate Campath;   Drug: RIC: Mini Busulfan
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Condition:   Hematological Malignancy
    Intervention:   Drug: Bortezomib
    Sponsor:   Henry Ford Health System
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Amyloidosis
    Interventions:   Other: blood collection;   Other: bone marrow collection
    Sponsor:   Shayna Sarosiek
    Recruiting

  • Condition:   Melanoma, Ocular
    Intervention:   Combination Product: Melphalan/HDS
    Sponsors:   Delcath Systems Inc.;   IQVIA Biotech
    Recruiting

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MEL-CFZ-TD-PACE
    Sponsors:   University of Arkansas;   Amgen
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Bendamustine Hydrochloride;   Drug: Cyclophosphamide;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Rhabdomyosarcoma;   Ewing Sarcoma;   Primitive Neuroectodermal Tumor;   Osteosarcoma;   Neuroblastoma
    Interventions:   Procedure: TCRαβ+/CD19+ depleted Haploidentical HSCT;   Drug: Zoledronate
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Dexamethasone;   Procedure: Autologous stem cell transplant;   Drug: Melphalan
    Sponsors:   Washington University School of Medicine;   Bristol-Myers Squibb;   Celgene
    Recruiting

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Ifosfamide;   Drug: Etoposide;   Biological: Rituximab;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Melphalan;   Other: Autologous HSCT;   Drug: Acalabrutinib
    Sponsors:   Swedish Medical Center;   Acerta Pharma BV
    Not yet recruiting

  • Conditions:   Hematological Disease;   Immune Deficiencies;   Solid Tumors;   Myelofibrosis;   Multiple Myeloma;   Lymphoma
    Interventions:   Radiation: Total Body Irradiation 1200 cGy;   Drug: Fludarabine;   Drug: Pre-Stem Cell Infusion Cyclophosphamide;   Drug: Pre-Stem Cell Infusion Mesna;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Drug: Post-Stem Cell Infusion Cyclophosphamide;   Drug: Post-Stem Cell Infusion Mesna;   Drug: Thiotepa
    Sponsor:   University of Rochester
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Acute Myeloid Leukemia With Variant MLL Translocations;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Chemotherapy-Related Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Gene Mutation;   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Allogeneic Natural Killer Cell Line NK-92;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Immune Deficiency Disorder;   Congenital Hematological Disorder;   Metabolism Disorder;   Aplastic Anemia;   Myelodysplastic Syndromes;   Chronic Leukemia;   Lymphoma;   Multiple Myeloma;   Solid Tumor
    Interventions:   Radiation: Total Body Irradiation 1200 cGy;   Radiation: Total Body Irradiation 200 cGy;   Drug: Cyclophosphamide;   Drug: Mesna;   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan
    Sponsor:   University of Rochester
    Recruiting

  • Condition:   Crohn's Disease
    Interventions:   Biological: autologous CD34-selected peripheral blood stem cells transplant;   Drug: Alemtuzumab;   Drug: ATG;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: G-CSF;   Drug: Mesna
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Ewing's Family Tumors;   Renal Tumors;   Hepatoblastoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Primary Malignant Brain Neoplasms;   Retinoblastoma;   Medulloblastoma;   Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET);   Atypical Teratoid/Rhabdoid Tumor (AT/RT);   CNS Tumors;   Germ Cell Tumors
    Interventions:   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Mesna;   Biological: G-CSF;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Leukapheresis;   Drug: Anti-seizure prophylaxis;   Drug: Ursodiol
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
    Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Fludarabine;   Drug: Alemtuzumab;   Drug: Melphalan
    Sponsor:   Emory University
    Recruiting

  • Conditions:   Sickle Cell-thalassemia Disease;   Thalassemia
    Intervention:   Drug: peripheral blood stem cell graft that are CD34+ selected
    Sponsors:   Catherine Bollard;   Children's Research Institute
    Recruiting

  • Conditions:   HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Metabolic Disorders;   Hematologic, Immune, or Bone Marrow Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan;   Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan
    Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Device: CliniMACS® CD34 Reagent System;   Drug: Fludarabine;   Drug: Melphalan;   Drug: anti-thymocyte globulin (rabbit);   Drug: Rituximab;   Radiation: Total Body Irradiation;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   B Acute Lymphoblastic Leukemia;   CD22 Positive;   Lymphocytic Neoplasm;   Lymphoma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Bendamustine;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Biological: Inotuzumab Ozogamicin;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Indolent Adult Non-Hodgkin Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Lenalidomide;   Drug: Melphalan;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
    Intervention:   Biological: CD34 Stem Cell Selection Therapy
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Severe Sickle Cell Disease;   Bone Marrow Failure Syndromes;   Metabolic Disorders;   Immunologic Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: RIC regimen;   Drug: GVHD prophylaxis regimen
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
    Interventions:   Drug: 75 approved agents;   Other: COXEN
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Juvenile Myelomonocytic Leukemia
    Interventions:   Biological: Stem Cell Transplant;   Drug: Preparative Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
    Intervention:   Genetic: Gene transfer
    Sponsors:   Aruvant Sciences GmbH;   Doris Duke Charitable Foundation
    Recruiting

  • Conditions:   Relapsing Multiple Sclerosis;   Relapsing Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Biological: Best Available Therapy (BAT)
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Not yet recruiting

  • Conditions:   Diffuse Large B-cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-cell Lymphoma (DLBCL);   Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    Interventions:   Procedure: leukapheresis;   Drug: Plerixafor;   Drug: carmustine, etoposide, cytarabine, melphalan;   Procedure: Autologous Stem Cell Transplantation
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Columbia University;   NorthShore University HealthSystem;   University of Rochester;   Medical College of Wisconsin;   University of Nebraska;   Sanofi;   University Hospitals Seidman Cancer Center
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
    Sponsors:   New York Medical College;   St. Baldrick's Foundation
    Recruiting

  • Conditions:   Sickle Cell Disease;   Graft Versus Host Disease
    Interventions:   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Methylprednisolone;   Drug: Meperidine;   Drug: Alemtuzumab;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Abatacept;   Procedure: Marrow infusion;   Drug: Sirolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Monica Bhatia
    Recruiting

  • Condition:   T Cell Non-Hodgkin Lymphoma
    Intervention:   Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
    Sponsors:   Memorial Sloan Kettering Cancer Center;   University of Washington;   Weill Medical College of Cornell University;   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Carfilzomib
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis;   Biological: Haplo HCT ≥55 and < 65 years old;   Biological: Haplo HCT ≥65 and ≤75 years old
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Daratumumab;   Procedure: autologous hematopoietic cell transplantation
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Janssen Pharmaceuticals
    Recruiting

  • Conditions:   Peritoneal Neoplasms;   Neoplasm Metastasis;   Adenocarcinoma;   Sarcoma
    Intervention:  
    Sponsor:   Edward-Elmhurst Health System
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   High-Risk Neuroblastoma;   NMYC Gene Amplification
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Drug: Isotretinoin;   Drug: Melphalan;   Biological: Sargramostim;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Vincristine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Genetic: Genetic Variation Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Leukemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: asparaginase;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: pegaspargase;   Drug: prednisolone;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation
    Sponsors:   Dutch Childhood Oncology Group;   BFM Germany;   CORS Monza Italy;   Associazione Italiana Ematologia Oncologia Pediatrica;   Australian and New Zealand Children's Oncology Group;   BFM Austria;   CLCG France Belgium Portugal;   COALL Germany;   CPH, Czech republic;   DFCI consortium USA;   FRALLE France;   Hong Kong;   MD Anderson USA;   NOPHO Scandinavian countries;   PINDA, Chile;   PPLLSG Poland;   Seattle USA;   SJCRH USA;   UKCCSG United Kingdom
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melflufen;   Drug: Dexamethasone
    Sponsors:   Oncopeptides AB;   Precision for Medicine, Oncology and Rare Disease
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melflufen;   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsor:   Oncopeptides AB
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melflufen;   Drug: Dexamethasone;   Drug: Bortezomib;   Drug: Daratumumab
    Sponsor:   Oncopeptides AB
    Recruiting

  • Conditions:   Clinical Stage 0 Cutaneous Melanoma AJCC v8;   Clinical Stage I Cutaneous Melanoma AJCC v8;   Clinical Stage IA Cutaneous Melanoma AJCC v8;   Clinical Stage IB Cutaneous Melanoma AJCC v8;   Clinical Stage II Cutaneous Melanoma AJCC v8;   Clinical Stage IIA Cutaneous Melanoma AJCC v8;   Clinical Stage IIB Cutaneous Melanoma AJCC v8;   Clinical Stage IIC Cutaneous Melanoma AJCC v8;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Colitis;   Diarrhea;   Malignant Genitourinary System Neoplasm;   Pathologic Stage 0 Cutaneous Melanoma AJCC v8;   Pathologic Stage I Cutaneous Melanoma AJCC v8;   Pathologic Stage IA Cutaneous Melanoma AJCC v8;   Pathologic Stage IB Cutaneous Melanoma AJCC v8;   Pathologic Stage II Cutaneous Melanoma AJCC v8;   Pathologic Stage IIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIC Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Other: Best Practice;   Other: Biospecimen Collection;   Procedure: Endoscopic Procedure;   Procedure: Fecal Microbiota Transplantation;   Biological: Infliximab;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Vedolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting